U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C48H66N5O10
Molecular Weight 873.0651
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOTEXAFIN

SMILES

CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc5nc(cc1n2)c(CCCO)c5C)c(C)c3CCCO

InChI

InChIKey=AHNIKTNNZJNCFN-CNEPGKQSSA-N
InChI=1S/C48H67N5O10/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40/h27-32,51,54-55H,7-26H2,1-6H3/b39-27-,40-28-,41-27-,42-28-,45-31-,46-32-,49-31+,49-43+,50-32+,50-44+

HIDE SMILES / InChI
Molecular Formula C48H69N5O10
Molecular Weight 876.089
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Motexafin is texaphyrin patented by pharmaceutical company Pharmacyclics, Inc. as chelating agents useful for the treatment of neoplastic and cardiovascular disease. The MRI-detectable gadolinium complex of motexafin was studied as a redox modulator that selectively targets tumor cells.

Originator

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
Motexafin gadolinium: a novel radiosensitizer for brain tumors.
2007-06
Motexafin gadolinium in the treatment of brain metastases.
2007-02
Patents

Patents

WO9735617
2
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:30:03 GMT 2025
Edited
by admin
on Mon Mar 31 18:30:03 GMT 2025
Record UNII
75QG9WGN4U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
8,11-IMINO-3,6:16,13-DINITRILO-1,18-BENZODIAZACYCLOEICOSINE-5,14-DIPROPANOL, 9,10-DIETHYL-20,21-BIS(2-(2-(2-METHOXYETHOXY)ETHOXY)ETHOXY)-4,15-DIMETHYL-
Preferred Name English
MOTEXAFIN
INN   WHO-DD  
INN  
Official Name English
Motexafin [WHO-DD]
Common Name English
motexafin [INN]
Common Name English
Code System Code Type Description
PUBCHEM
151071
Created by admin on Mon Mar 31 18:30:03 GMT 2025 , Edited by admin on Mon Mar 31 18:30:03 GMT 2025
PRIMARY
FDA UNII
75QG9WGN4U
Created by admin on Mon Mar 31 18:30:03 GMT 2025 , Edited by admin on Mon Mar 31 18:30:03 GMT 2025
PRIMARY
NCI_THESAURUS
C166993
Created by admin on Mon Mar 31 18:30:03 GMT 2025 , Edited by admin on Mon Mar 31 18:30:03 GMT 2025
PRIMARY
SMS_ID
300000036873
Created by admin on Mon Mar 31 18:30:03 GMT 2025 , Edited by admin on Mon Mar 31 18:30:03 GMT 2025
PRIMARY
ChEMBL
CHEMBL2104414
Created by admin on Mon Mar 31 18:30:03 GMT 2025 , Edited by admin on Mon Mar 31 18:30:03 GMT 2025
PRIMARY
CAS
189752-49-6
Created by admin on Mon Mar 31 18:30:03 GMT 2025 , Edited by admin on Mon Mar 31 18:30:03 GMT 2025
PRIMARY
INN
7962
Created by admin on Mon Mar 31 18:30:03 GMT 2025 , Edited by admin on Mon Mar 31 18:30:03 GMT 2025
PRIMARY
Related Record Type Details
Structure of MOTEXAFIN LUTETIUM ANHYDROUS
LABELED -> NON-LABELED
Structure of MOTEXAFIN GADOLINIUM ANHYDROUS
LABELED -> NON-LABELED
Structure of MOTEXAFIN LUTETIUM
LABELED -> NON-LABELED
Structure of MOTEXAFIN GADOLINIUM
LABELED -> NON-LABELED
Structure of Motexafin hydrochloride
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of MOTEXAFIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966